C ardiovascular disease (CVD) care in the United States will cost an estimated $109 billion in 1992.1 Despite the nearly 50% decline in the CVD death rate in the last two decades, approximately one third of the 1.5 million people who will have a myocardial infarction this year will die.' New programs to reduce these societal costs are health care and research priorities. Given the large numbers of individuals at risk for CVD and competition for health care resources, clinical policy must consider costs in addition to potential effectiveness. Cost-effectiveness analysis is being used to assess quality and cost implications and to provide policy makers and clinicians with a framework for evaluation of alternative strategies.
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Cost-effectiveness analysis, as well as meta-analysis, decision analysis, and cost-benefit analysis, provide models for estimating the impact of screening or treating a given condition. 23 Cost-effectiveness analyses provide models for estimating the impact of proposed programs or interventions that may not be easily addressed using traditional clinical research methods. These techniques permit linkages from different sources, including epidemiology, clinical trials, and cost and outcome studies to address clinical or research questions. Outcome, or effectiveness, is measured with end points such as morbidity, mortality, years of life saved, and estimates of health status and quality of life.2 Cost-effectiveness studies can also address the incremental effectiveness of given interventions by varying the inputs or assumptions used in the model.
In this issue of Circulation, Goldman and colleagues4 present a summary of a conference sponsored by the National Heart, Lung, and Blood Institute National Cholesterol Education Program (NCEP) on the cost and health implications of cholesterol treatment. This landmark report, based on research and expert panel reports, reviews current cost-effectiveness research and the cost implications of cholesterol management under a variety of clinical conditions. This report highlights The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association. the usefulness of cost-effectiveness research in developing and refining health policy and comparing the cost of cholesterol reduction programs with other health programs. The conference panels concluded that the framework presented should be used in the "evolution and implementation of future national cholesterol guidelines.. . (and) the development of national health policy for cardiovascular diseases." Several conference findings have direct impact on clinicians and clinical policy. The cost-effectiveness findings support the major recommendations of the NCEP Adult Treatment Panel report,5 including the population approach for dietary fat reduction and treatment of individuals with multiple risk factors, dyslipidemias, or known atherosclerosis. The analyses strongly support the aggressive treatment of cholesterol disorders in patients with preexisting atherosclerosis. 4, 6, 7 Clinicians must now recognize that overwhelming clinical trial and cost-effectiveness evidence endorses the benefits of cholesterol treatment in high-risk persons. Furthermore, medical education programs should emphasize these major findings.
The conference findings suggest further evaluation and refinement of other aspects of the NCEP Adult Treatment Panel.5 Conclusions about primary prevention, particularly in men without risk factors, women, and the elderly, were less certain because of the lack of data. Using medication for primary prevention was not generally considered cost-effective unless other risk factors were present and the medications were inexpensive and highly effective (e.g., niacin). The findings regarding primary prevention question the cost-effectiveness of prescribed dietary therapy for low-risk people; it is important to note that a population approach for recommending a low-fat eating pattern was considered cost-effective and is recommended as a national policy because of its potential benefit for many problems, including obesity, adult-onset diabetes, cancer, and cardiovascular disease. Recommendations regarding cholesterol screening and lipoprotein measurement were not addressed in this report. 4 The limitations of cost-effectiveness research are important to consider in interpreting the conference conclusions. Cost-effectiveness analyses require a series of assumptions of costs for the construction of each model. Variations in these assumptions and their resultant input into the mathematical model may have significant effects on outputs. Failing to test all appropriate assumptions or using incomplete data may produce inaccurate or incomplete conclusions. This has, in fact, been a criticism of previous analyses of cholesterol lowering.8'9 Inappropriate assumptions or methodological errors could lead to inappropriate policy or practice decisions.8'10 Those who create clinical guidelines and policy are often hampered by a lack of clinical trial, outcome, and cost data needed to construct valid cost-effectiveness analyses. Clinical trial data on cholesterol treatment of women, children, young men, and the elderly is insufficient to develop comprehensive policy. Previous primary prevention trials of cholesterol treatment have not been designed to examine mortality as a primary outcome because of limitations in cost, sample size, and duration, which limits mortality estimates available for cost-effective models."1 '12 Estimates of treatment efficacy from clinical trials may also have important limitations. Trial results may not have reached their full potential because of limits in design or limited availability of effective medications when trials were designed. For example, dietary trial results are hampered by heterogeneous responses to dietary alterations and depend on the quality of a nonstandardized counseling intervention. Most trials have studied moderate-fat (30-35% total fat by calories) rather than low-fat (20% total fat by calories) diets, which could improve treatment effectiveness.13 The treatment potential in primary prevention pharmacological trials was diminished by the use of a single agent to treat a variety of cholesterol disorders rather than specific therapy based on the individual metabolic disorder."1-'4 A recent reanalysis of the Helsinki Heart Trial12 found a significantly improved outcome in subjects with combined dyslipidemias treated with gemfibrozil compared with isolated elevations of low density lipoprotein (LDL) cholesterol. Gemfibrozil is primarily effective for the treatment of disorders with elevated triglycerides.5"12"4 The use of a bile acid sequestrant, which has a modest treatment effect and is used primarily in disorders with elevated LDL cholesterol and normal triglycerides, was studied in men with triglycerides as high as 300 mg/dl in the Lipids Research Clinics Trial." Treatment with agents indicated for specific lipoprotein abnormalities and newer, more potent agents such as the HMG CoA reductase inhibitors may be more cost-effective under certain conditions despite higher costs per dose. 15 The findings by Goldman et al4 also suggest important research priorities for developing future cholesterol policy and clinical guidelines. These research priorities include primary and secondary prevention trials of very-low-fat diets; medications that are specific to individual dyslipidemias (isolated low high density lipoprotein cholesterol, combined dyslipidemias with elevated triglycerides, and lipoprotein a); and nutritional and medication trials in high-risk women, young men, children, and the elderly. Estimates of quality of life and health status of persons participating in the nutritional or medical trials for cholesterol treatment should be included in cost-effectiveness analyses.
Clinical trials conducted in highly selected patients and in tightly controlled conditions may not yield similar results in the community practice environment. Despite a dramatic shift in physician attitudes and prescriptions for cholesterol treatment, current research16-19 indicates that physician practice for cholesterol management is below the standards recommended by the NCEP guidelines.5 A number of barriers, including insufficient clinical trial evidence and concerns about the costs of various treatment strategies, limit physician endorsement and use of cholesterol guidelines.16 '20-22 Assumptions about physician management in cost-effectiveness analyses may not be accurate. Therefore, a major goal for policy development and research is to obtain more data on the effectiveness and costs of educating health care providers and to implement guidelines in community practice. Collecting cost data related to interventions in clinical and community trials will also enhance the quality of cost-effectiveness analyses and the resultant policy on which it is based.
The NCEP should be commended for incorporating alternative approaches in the development and refinement of clinical policy and guidelines. The NCEP has also incorporated cost data into the recently published guidelines for blood cholesterol in children and adolescents. 23 In an era of cost containment, prevention programs must justify costs. While cost-effectiveness analysis is a major effort and commitment, the NCEP evaluations set a standard for national health policy.
